ID   SPTC2_HUMAN             Reviewed;         562 AA.
AC   O15270; Q16685;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   10-MAY-2017, entry version 161.
DE   RecName: Full=Serine palmitoyltransferase 2;
DE            EC=2.3.1.50;
DE   AltName: Full=Long chain base biosynthesis protein 2;
DE            Short=LCB 2;
DE   AltName: Full=Long chain base biosynthesis protein 2a;
DE            Short=LCB2a;
DE   AltName: Full=Serine-palmitoyl-CoA transferase 2;
DE            Short=SPT 2;
GN   Name=SPTLC2; Synonyms=KIAA0526, LCB2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=9363775; DOI=10.1111/j.1432-1033.1997.00239.x;
RA   Weiss B., Stoffel W.;
RT   "Human and murine serine-palmitoyl-CoA transferase. Cloning,
RT   expression and characterization of the key enzyme in sphingolipid
RT   synthesis.";
RL   Eur. J. Biochem. 249:239-247(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=9628581; DOI=10.1093/dnares/5.1.31;
RA   Nagase T., Ishikawa K., Miyajima N., Tanaka A., Kotani H., Nomura N.,
RA   Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. IX.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 5:31-39(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 60-470.
RC   TISSUE=Pancreatic islet;
RX   PubMed=8921873; DOI=10.1016/0378-1119(96)00309-5;
RA   Nagiec M.M., Lester R.L., Dickson R.C.;
RT   "Sphingolipid synthesis: identification and characterization of
RT   mammalian cDNAs encoding the Lcb2 subunit of serine
RT   palmitoyltransferase.";
RL   Gene 177:237-241(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 68-144.
RC   TISSUE=Pancreatic islet;
RX   PubMed=7506601; DOI=10.1093/hmg/2.11.1793;
RA   Takeda J., Yano H., Eng S., Zeng Y., Bell G.I.;
RT   "A molecular inventory of human pancreatic islets: sequence analysis
RT   of 1000 cDNA clones.";
RL   Hum. Mol. Genet. 2:1793-1798(1993).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=17023427; DOI=10.1074/jbc.M608066200;
RA   Hornemann T., Richard S., Ruetti M.F., Wei Y., von Eckardstein A.;
RT   "Cloning and initial characterization of a new subunit for mammalian
RT   serine-palmitoyltransferase.";
RL   J. Biol. Chem. 281:37275-37281(2006).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND IDENTIFICATION IN THE SPT COMPLEX.
RX   PubMed=19416851; DOI=10.1073/pnas.0811269106;
RA   Han G., Gupta S.D., Gable K., Niranjanakumari S., Moitra P.,
RA   Eichler F., Brown R.H. Jr., Harmon J.M., Dunn T.M.;
RT   "Identification of small subunits of mammalian serine
RT   palmitoyltransferase that confer distinct acyl-CoA substrate
RT   specificities.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:8186-8191(2009).
RN   [9]
RP   FUNCTION, VARIANTS HSAN1C MET-359; VAL-382 AND PHE-504, AND
RP   CHARACTERIZATION OF VARIANTS HSAN1C MET-359; VAL-382 AND PHE-504.
RX   PubMed=20920666; DOI=10.1016/j.ajhg.2010.09.010;
RA   Rotthier A., Auer-Grumbach M., Janssens K., Baets J., Penno A.,
RA   Almeida-Souza L., Van Hoof K., Jacobs A., De Vriendt E.,
RA   Schlotter-Weigel B., Loscher W., Vondracek P., Seeman P.,
RA   De Jonghe P., Van Dijck P., Jordanova A., Hornemann T., Timmerman V.;
RT   "Mutations in the SPTLC2 subunit of serine palmitoyltransferase cause
RT   hereditary sensory and autonomic neuropathy type I.";
RL   Am. J. Hum. Genet. 87:513-522(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   VARIANT HSAN1C PRO-182, CHARACTERIZATION OF VARIANT HSAN1C PRO-182,
RP   AND PATHOLOGICAL MECHANISM.
RX   PubMed=23658386; DOI=10.1212/WNL.0b013e318295d789;
RA   Murphy S.M., Ernst D., Wei Y., Laura M., Liu Y.T., Polke J., Blake J.,
RA   Winer J., Houlden H., Hornemann T., Reilly M.M.;
RT   "Hereditary sensory and autonomic neuropathy type 1 (HSANI) caused by
RT   a novel mutation in SPTLC2.";
RL   Neurology 80:2106-2111(2013).
CC   -!- FUNCTION: Serine palmitoyltransferase (SPT). The heterodimer
CC       formed with LCB1/SPTLC1 constitutes the catalytic core. The
CC       composition of the serine palmitoyltransferase (SPT) complex
CC       determines the substrate preference. The SPTLC1-SPTLC2-SPTSSA
CC       complex shows a strong preference for C16-CoA substrate, while the
CC       SPTLC1-SPTLC2-SPTSSB complex displays a preference for C18-CoA
CC       substrate. {ECO:0000269|PubMed:19416851,
CC       ECO:0000269|PubMed:20920666}.
CC   -!- CATALYTIC ACTIVITY: Palmitoyl-CoA + L-serine = CoA + 3-dehydro-D-
CC       sphinganine + CO(2). {ECO:0000269|PubMed:19416851}.
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC         Evidence={ECO:0000250};
CC   -!- PATHWAY: Lipid metabolism; sphingolipid metabolism.
CC   -!- SUBUNIT: Heterodimer with SPTLC1. Component of the serine
CC       palmitoyltransferase (SPT) complex, composed of LCB1/SPTLC1, LCB2
CC       (SPTLC2 or SPTLC3) and ssPT (SPTSSA and SPTSSB).
CC       {ECO:0000269|PubMed:19416851}.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000250}; Single-pass membrane protein {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC       {ECO:0000269|PubMed:17023427}.
CC   -!- DISEASE: Neuropathy, hereditary sensory and autonomic, 1C (HSAN1C)
CC       [MIM:613640]: A form of hereditary sensory and autonomic
CC       neuropathy, a genetically and clinically heterogeneous group of
CC       disorders characterized by degeneration of dorsal root and
CC       autonomic ganglion cells, and by prominent sensory abnormalities
CC       with a variable degree of motor and autonomic dysfunction. The
CC       neurological phenotype is often complicated by severe infections,
CC       osteomyelitis, and amputations. HSAN1C symptoms include loss of
CC       touch and vibration in the feet, dysesthesia and severe panmodal
CC       sensory loss in the upper and lower limbs, distal lower limb
CC       sensory loss with ulceration and osteomyelitis, and distal muscle
CC       weakness. {ECO:0000269|PubMed:20920666,
CC       ECO:0000269|PubMed:23658386}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. SPTLC2
CC       disease mutations cause a shift in the substrate specificity of
CC       SPT resulting in the alternative use of L-alanine and L-glycine
CC       over its canonical substrate L-serine. This leads to the
CC       production of 1-deoxysphingolipids that cannot be correctly
CC       metabolized (PubMed:23658386). {ECO:0000269|PubMed:23658386}.
CC   -!- SIMILARITY: Belongs to the class-II pyridoxal-phosphate-dependent
CC       aminotransferase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA25452.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y08686; CAA69942.1; -; mRNA.
DR   EMBL; AB011098; BAA25452.2; ALT_INIT; mRNA.
DR   EMBL; AF111168; AAD09621.1; -; Genomic_DNA.
DR   EMBL; BC005123; AAH05123.1; -; mRNA.
DR   EMBL; U15555; AAC50871.1; -; mRNA.
DR   CCDS; CCDS9865.1; -.
DR   PIR; I38873; I38873.
DR   RefSeq; NP_004854.1; NM_004863.3.
DR   UniGene; Hs.435661; -.
DR   ProteinModelPortal; O15270; -.
DR   SMR; O15270; -.
DR   BioGrid; 114894; 13.
DR   DIP; DIP-34604N; -.
DR   IntAct; O15270; 10.
DR   STRING; 9606.ENSP00000216484; -.
DR   BindingDB; O15270; -.
DR   ChEMBL; CHEMBL1250344; -.
DR   DrugBank; DB00133; L-Serine.
DR   DrugBank; DB00114; Pyridoxal Phosphate.
DR   iPTMnet; O15270; -.
DR   PhosphoSitePlus; O15270; -.
DR   BioMuta; SPTLC2; -.
DR   EPD; O15270; -.
DR   MaxQB; O15270; -.
DR   PaxDb; O15270; -.
DR   PeptideAtlas; O15270; -.
DR   PRIDE; O15270; -.
DR   DNASU; 9517; -.
DR   Ensembl; ENST00000216484; ENSP00000216484; ENSG00000100596.
DR   GeneID; 9517; -.
DR   KEGG; hsa:9517; -.
DR   UCSC; uc001xub.4; human.
DR   CTD; 9517; -.
DR   DisGeNET; 9517; -.
DR   GeneCards; SPTLC2; -.
DR   HGNC; HGNC:11278; SPTLC2.
DR   HPA; HPA027552; -.
DR   MalaCards; SPTLC2; -.
DR   MIM; 605713; gene.
DR   MIM; 613640; phenotype.
DR   neXtProt; NX_O15270; -.
DR   OpenTargets; ENSG00000100596; -.
DR   Orphanet; 36386; Hereditary sensory and autonomic neuropathy type 1.
DR   PharmGKB; PA36107; -.
DR   eggNOG; KOG1357; Eukaryota.
DR   eggNOG; COG0156; LUCA.
DR   GeneTree; ENSGT00550000074678; -.
DR   HOGENOM; HOG000206826; -.
DR   HOVERGEN; HBG002230; -.
DR   InParanoid; O15270; -.
DR   KO; K00654; -.
DR   OMA; TGACQEA; -.
DR   OrthoDB; EOG091G0558; -.
DR   PhylomeDB; O15270; -.
DR   TreeFam; TF300452; -.
DR   BioCyc; MetaCyc:HS02117-MONOMER; -.
DR   BRENDA; 2.3.1.50; 2681.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   UniPathway; UPA00222; -.
DR   ChiTaRS; SPTLC2; human.
DR   GeneWiki; SPTLC2; -.
DR   GenomeRNAi; 9517; -.
DR   PRO; PR:O15270; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000100596; -.
DR   CleanEx; HS_SPTLC2; -.
DR   ExpressionAtlas; O15270; baseline and differential.
DR   Genevisible; O15270; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0017059; C:serine C-palmitoyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IEA:InterPro.
DR   GO; GO:0004758; F:serine C-palmitoyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0046513; P:ceramide biosynthetic process; IDA:MGI.
DR   GO; GO:1904504; P:positive regulation of lipophagy; IDA:MGI.
DR   GO; GO:0046511; P:sphinganine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; IDA:MGI.
DR   GO; GO:0006686; P:sphingomyelin biosynthetic process; IEA:Ensembl.
DR   GO; GO:0046512; P:sphingosine biosynthetic process; IEA:Ensembl.
DR   Gene3D; 3.40.640.10; -; 1.
DR   Gene3D; 3.90.1150.10; -; 1.
DR   InterPro; IPR001917; Aminotrans_II_pyridoxalP_BS.
DR   InterPro; IPR004839; Aminotransferase_I/II.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major_sub1.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_sub2.
DR   Pfam; PF00155; Aminotran_1_2; 1.
DR   SUPFAM; SSF53383; SSF53383; 1.
DR   PROSITE; PS00599; AA_TRANSFER_CLASS_2; 1.
PE   1: Evidence at protein level;
KW   Acyltransferase; Complete proteome; Disease mutation;
KW   Endoplasmic reticulum; Lipid metabolism; Membrane; Neuropathy;
KW   Pyridoxal phosphate; Reference proteome; Sphingolipid metabolism;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1    562       Serine palmitoyltransferase 2.
FT                                /FTId=PRO_0000163858.
FT   TRANSMEM     67     87       Helical. {ECO:0000255}.
FT   MOD_RES     379    379       N6-(pyridoxal phosphate)lysine.
FT                                {ECO:0000250}.
FT   VARIANT     182    182       A -> P (in HSAN1C; reduced activity with
FT                                L-serine as substrate; increased activity
FT                                toward L-alanine resulting in the
FT                                accumulation of 1-deoxy-sphinganine;
FT                                dbSNP:rs864621998).
FT                                {ECO:0000269|PubMed:23658386}.
FT                                /FTId=VAR_069525.
FT   VARIANT     359    359       V -> M (in HSAN1C; partial loss of normal
FT                                activity as measured by reduced formation
FT                                of sphinganine; affects enzymatic
FT                                affinity resulting in the accumulation of
FT                                the alternative metabolite 1-deoxy-
FT                                sphinganine; dbSNP:rs267607090).
FT                                {ECO:0000269|PubMed:20920666}.
FT                                /FTId=VAR_064798.
FT   VARIANT     382    382       G -> V (in HSAN1C; complete loss of
FT                                normal activity as measured by lack of
FT                                formation of sphinganine; affects
FT                                enzymatic affinity resulting in the
FT                                accumulation of the alternative
FT                                metabolite 1-deoxy-sphinganine;
FT                                dbSNP:rs267607089).
FT                                {ECO:0000269|PubMed:20920666}.
FT                                /FTId=VAR_064799.
FT   VARIANT     504    504       I -> F (in HSAN1C; partial loss of normal
FT                                activity as measured by reduced formation
FT                                of sphinganine; affects enzymatic
FT                                affinity resulting in the accumulation of
FT                                the alternative metabolite 1-deoxy-
FT                                sphinganine; dbSNP:rs267607091).
FT                                {ECO:0000269|PubMed:20920666}.
FT                                /FTId=VAR_064800.
FT   CONFLICT     61     64       EAFE -> TLAR (in Ref. 5; AAC50871).
FT                                {ECO:0000305}.
FT   CONFLICT    436    469       KECVQQLAENTRYFRRRLKEMGFIIYGNEDSPVV -> NGI
FT                                TIHEVVQTRNTYHRFSPLSPVFSHQCLWIML (in Ref.
FT                                5). {ECO:0000305}.
SQ   SEQUENCE   562 AA;  62924 MW;  0C1AA1E233DE36F1 CRC64;
     MRPEPGGCCC RRTVRANGCV ANGEVRNGYV RSSAAAAAAA AAGQIHHVTQ NGGLYKRPFN
     EAFEETPMLV AVLTYVGYGV LTLFGYLRDF LRYWRIEKCH HATEREEQKD FVSLYQDFEN
     FYTRNLYMRI RDNWNRPICS VPGARVDIME RQSHDYNWSF KYTGNIIKGV INMGSYNYLG
     FARNTGSCQE AAAKVLEEYG AGVCSTRQEI GNLDKHEELE ELVARFLGVE AAMAYGMGFA
     TNSMNIPALV GKGCLILSDE LNHASLVLGA RLSGATIRIF KHNNMQSLEK LLKDAIVYGQ
     PRTRRPWKKI LILVEGIYSM EGSIVRLPEV IALKKKYKAY LYLDEAHSIG ALGPTGRGVV
     EYFGLDPEDV DVMMGTFTKS FGASGGYIGG KKELIDYLRT HSHSAVYATS LSPPVVEQII
     TSMKCIMGQD GTSLGKECVQ QLAENTRYFR RRLKEMGFII YGNEDSPVVP LMLYMPAKIG
     AFGREMLKRN IGVVVVGFPA TPIIESRARF CLSAAHTKEI LDTALKEIDE VGDLLQLKYS
     RHRLVPLLDR PFDETTYEET ED
//
